- Home
- CCEL vs IXHL Comparison
CCEL vs IXHL Comparison
Compare CCEL & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCEL | IXHL |
|---|---|---|
| Founded | 1989 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Managed Health Care | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 37.0M |
| IPO Year | 2022 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CCEL | IXHL |
|---|---|---|
| Price | $3.46 | $3.82 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 282.8K |
| Earning Date | 04-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $25,384,279.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $332.00 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $2.72 | $0.16 |
| 52 Week High | $5.43 | $6.39 |
Technical Indicators
Market Signals| Indicator | CCEL | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 56.84 |
| Support Level | $3.11 | $2.68 |
| Resistance Level | $3.92 | $4.22 |
| Average True Range (ATR) | 0.26 | 0.36 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 37.39 | 64.35 |
Price Performance
Historical ComparisonAbout CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.